Loading
Companies and charities give or discount cancer drugs in poorer countries, but nobody records whether the patients did well. Make a simple outcome record part of every programme.
Access programmes (donations, tiered pricing, patient assistance) treat hundreds of thousands of patients in low- and middle-income countries with no systematic outcome data, so we cannot tell whether treatments developed in high-income trials work under different conditions of nutrition, comorbidity, diagnostics and supportive care. The proposal makes a minimal outcome record (diagnosis, stage, treatment, vital status at 12 months) a condition of participation, captured via mobile registry tools and pooled by a neutral steward.
Shares Assessment of the Clinical Benefit of Cancer Drugs Receiving Accelerated Approval, Real-world evidence, Weak real-world evidence and registries.
Shares Assessment of the Clinical Benefit of Cancer Drugs Receiving Accelerated Approval, Real-world evidence, Weak real-world evidence and registries.
Shares Assessment of the Clinical Benefit of Cancer Drugs Receiving Accelerated Approval, Real-world evidence, Weak real-world evidence and registries.
Shares Assessment of the Clinical Benefit of Cancer Drugs Receiving Accelerated Approval, Real-world evidence, Weak real-world evidence and registries.
Shares Assessment of the Clinical Benefit of Cancer Drugs Receiving Accelerated Approval, Real-world evidence, Weak real-world evidence and registries.
Shares Assessment of the Clinical Benefit of Cancer Drugs Receiving Accelerated Approval, Real-world evidence, Weak real-world evidence and registries.
Shares Assessment of the Clinical Benefit of Cancer Drugs Receiving Accelerated Approval, Real-world evidence, Weak real-world evidence and registries.
Shares Assessment of the Clinical Benefit of Cancer Drugs Receiving Accelerated Approval, Real-world evidence, Weak real-world evidence and registries.